CTS Corporation (CTS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed signals: while aerospace, defense, industrial, and medical markets show strong performance, the transportation sector struggles, and EPS guidance was lowered due to tax impacts. Positive aspects include strong market growth and the SyQwest acquisition meeting expectations, but the adverse tax impact and transportation market softness temper enthusiasm. The Q&A session highlighted some concerns, such as unclear management responses and ongoing tax issues. Given the balance of positive and negative factors, the stock price is likely to remain stable over the next two weeks.
Key Financial Performance
Sales Sales in the third quarter were $143 million, up 8% from $132 million in the third quarter of 2024. Diversified end market sales increased 22% year-over-year, while transportation sales were down 7% from the same period last year due to softness in commercial vehicle products.
Gross Margin Adjusted gross margin was 38.9% in the third quarter, up 66 basis points compared to the third quarter of 2024. This improvement was attributed to operational execution and minimal impact from tariffs.
Adjusted EBITDA Adjusted EBITDA was 23.8% in the quarter, a reduction of 55 basis points compared to the third quarter of 2024, but an improvement of 86 basis points sequentially. The year-over-year reduction was not explicitly explained.
Adjusted Diluted Earnings Per Share Adjusted diluted earnings were $0.60 per share, down from $0.61 in the third quarter of 2024. The decrease was primarily due to an unfavorable impact from recent U.S. tax legislation.
Operating Cash Flow Operating cash flow in the third quarter was $29 million, down from $35 million in the third quarter of 2024. The reasons for this decline were not explicitly mentioned.
SyQwest Sales SyQwest sales were $8.8 million during the quarter, contributing to the growth in aerospace and defense sales, which were up 23% year-over-year.
Transportation Sales Transportation sales were $58.5 million in the third quarter, down approximately 7% from the same period last year due to softness in commercial vehicle products.
Aerospace and Defense Sales Aerospace and defense sales in the third quarter were up 23% from the third quarter of 2024. This growth was supported by SyQwest revenues and multiple orders for sonar applications.
Industrial Market Sales Sales in the industrial market were up 21% year-over-year and 9% sequentially, driven by a steady recovery with OEMs and distribution customers.
Medical End Market Sales Medical end market sales were up 22% compared to the same period in 2024, with strong demand for minimally invasive applications and therapeutic products.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New braking sensor application: Added to the transportation portfolio, strengthening long-term capability in footwall presence.
COBROS technology: A new platform for electric motor control, simplifying design, reducing weight, and enhancing control precision.
Medical market: Strong growth in minimally invasive applications, diagnostic ultrasound, and therapeutic products. Added two new customers for diagnostic ultrasound.
Aerospace and defense: SyQwest team awarded a $5 million naval defense contract with potential for additional awards. Sales up 23% YoY, with strong bookings and multiple sonar application orders.
Industrial market: Steady recovery with 21% YoY sales growth. Wins in industrial printing, EMC, temperature sensing, and heat pump applications. Added a new customer for position sensing.
Gross margin improvement: Expanded by 66 basis points YoY to 38.9%.
Operational cash flow: Generated $29 million in Q3 2025.
Adjusted EBITDA: Improved sequentially to 23.8%.
Diversification strategy: Focus on moving from component supplier to sensors, transducers, and subsystems. Diversified end markets now 59% of revenue, up from 52% YoY.
SyQwest acquisition: Driving growth in aerospace and defense with a strong pipeline and seasonality in revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Transportation Sales Decline: Transportation sales were down 7% from the same period last year due to softness in commercial vehicle products. This decline could impact overall revenue and profitability.
Tariff and Geopolitical Environment: The company is closely monitoring the uncertain tariff and geopolitical environment, which could affect costs, pricing, and supply chain dynamics.
Supply Chain Risks: Potential supply chain issues related to rare earth, aluminum, and semiconductors are being monitored, though no immediate impact has been observed.
Electric Vehicle Market Softness: Electric vehicle penetration rates have softened in some regions, which could impact demand for related products.
Seasonality in SyQwest Revenue: Revenue from the SyQwest acquisition may be influenced by the timing of U.S. government funding approvals, introducing seasonality and potential revenue fluctuations.
Tax Legislation Impact: Recent U.S. tax legislation changes had an adverse impact of approximately $0.03 on adjusted earnings per diluted share for the third quarter.
Environmental Reserve Increase: A $4.2 million increase in reserve related to an EPA cost reimbursement claim for a prior environmental matter impacted financial results.
Commercial Vehicle Demand Softness: General softness in commercial vehicle demand is anticipated in the fourth quarter, which could affect transportation sales.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Medical End Market: Demand remains strong for therapeutic products, with increased volumes expected in 2026. Growth in portable ultrasound diagnostics and therapeutics is anticipated to enhance the company's growth profile over time.
Aerospace and Defense: Revenue is expected to grow due to the timing of orders and momentum from the SyQwest acquisition. Solid bookings are anticipated in the last quarter of 2025, with continued momentum into 2026.
Industrial Market: Demand is expected to remain healthy for the balance of 2025, with a steady recovery in OEMs and distribution customers. Longer-term growth prospects are supported by trends in automation, connectivity, and efficiency.
Transportation Market: Production volumes are expected to remain soft due to tariff impacts and customer demand. The North American light vehicle market is forecasted at 15 million units, European production at 16 million units, and China volumes at 30 million units. Electric vehicle penetration rates have softened in some regions, while hybrid adoption continues to improve. General softness in commercial vehicle demand is anticipated in the fourth quarter of 2025.
SyQwest Revenue: Revenue from the SyQwest acquisition is expected to maintain positive momentum through the end of 2025, with some seasonality influenced by U.S. government funding approvals.
Sales Guidance: Sales are projected in the range of $535 million to $545 million for 2025.
Adjusted Diluted EPS Guidance: Adjusted diluted EPS is expected to be in the range of $2.20 to $2.25 for 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: In total, we returned $44 million to shareholders through dividends and share buybacks in the 3 quarters of 2025.
Share Buyback: During the quarter, we repurchased 400,000 shares of CTS stock for approximately $17 million. We have $21 million remaining under our current share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why was the midpoint of revenue guidance raised but the midpoint of EPS guidance lowered?
A:The revenue guidance was raised due to positive momentum in industrial, aerospace and defense, and therapeutics markets, despite some headwinds in CV and diagnostics. The EPS guidance was lowered primarily due to adverse tax impacts caused by the mix of earnings and tax legislation.
Q:What are transportation customers signaling about 2026 production rates?
A:The transportation market for 2026 is mixed, with some OEMs being positive and others negative. Light vehicle sales showed a small incremental increase in low single digits, and bookings were solid. The market is expected to remain mixed next year.
Q:How should end markets be ranked in terms of gross margin contribution?
A:Management did not provide a specific ranking of end markets by gross margin contribution. They noted that margins vary by product line rather than end market, with single crystal products having higher margins than others. Diversified end markets like medical, industrial, aerospace, and defense have decent margins, while transportation lags behind.
Q:Will the adverse tax impact go away in 2026?
A:The adverse tax impact from tax legislation is expected to continue into 2026, with a similar tax rate as 2025 (21%-23%). Management will continue exploring opportunities for tax efficiency.
Q:How should inventory levels in the transportation channel be viewed?
A:Inventory levels in the transportation channel, particularly for light vehicles, are trending around 50 days of supply, which is considered normal. There is some softness in the commercial vehicle market, which is being monitored.
Q:Does the SyQwest acquisition meet revenue contribution targets?
A:The SyQwest acquisition is meeting expectations, with a step-up in revenues from Q2 to Q3 and further increases expected. Seasonality is anticipated next year due to government funding, and the company is optimistic about the pipeline of opportunities.
Q:What caused the increase in operating expenses this quarter?
A:The increase in operating expenses was primarily due to a $4.2 million increase in reserves and a year-over-year increase in equity-based compensation adjustments.
Q:Is management more positive about industrial end markets?
A:Yes, management is positive about industrial end markets, citing a 9% sequential improvement and over 20% year-on-year growth, along with strong distribution-related sales.
Q:Will diagnostics improve in the medical market?
A:Diagnostics in the medical market is currently weaker but solid overall. Improvement is expected more significantly next year, while therapeutics show strong momentum.
Q:How is the company navigating tariffs?
A:The company mitigates tariff impacts by keeping production and sales within the same regions (Asia, Europe, North America) and working with suppliers and customers to manage costs. They are also monitoring potential exposure from USMCA changes.
Q:Does the fire at Ford's aluminum supplier impact the company?
A:The fire at Ford's aluminum supplier, Novelis, has not had a direct impact on the company so far, but it is being monitored.
Q:Review of Unclear Management Responses
A:Management avoided directly ranking end markets by gross margin contribution, instead discussing variations by product line. They also provided limited details on the specific impact of the SyQwest acquisition beyond general optimism and did not elaborate on the potential long-term effects of the fire at Ford's aluminum supplier.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bookings period
China
Demand
EVs
OEMs
SyQwest acquisition
Transportation sale
application
booking
brake
capability
control
cost
customer
demand
digit
distribution
flow
hybrid
increase
momentum
order
pacemaker
platform award
position
production
prospect
rate
recovery
sensing
sensor
skin
supplier
tariff environment
technology
term
therapeutic
ultrasound
unit
vehicle actuator
volume
CTS Transcript
CTS Corporation (CTS) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call highlights double-digit sales growth due to effective diversification, particularly in industrial and medical markets, with stable transportation revenue. Despite potential risks, the strong operational execution and strategic positioning suggest positive sentiment. The absence of clear concerns in the Q&A further supports this outlook. However, no shareholder return plans were discussed, keeping the sentiment from being 'strong positive.'
CTS Corporation (CTS) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call summary indicates strong financial performance with increased sales in key markets like Medical and Industrial. Despite a decline in Transportation, new business awards and operational efficiencies improved EBITDA margins. The Q&A session highlighted strong demand and product development, though some management responses lacked clarity. Overall, the positive sales growth, improved margins, and strategic advancements in diversified markets suggest a positive stock price movement in the short term.
CTS Corporation (CTS) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call reflects mixed signals: while aerospace, defense, industrial, and medical markets show strong performance, the transportation sector struggles, and EPS guidance was lowered due to tax impacts. Positive aspects include strong market growth and the SyQwest acquisition meeting expectations, but the adverse tax impact and transportation market softness temper enthusiasm. The Q&A session highlighted some concerns, such as unclear management responses and ongoing tax issues. Given the balance of positive and negative factors, the stock price is likely to remain stable over the next two weeks.
CTS Corporation (CTS) Q2 2025 Earnings Call Transcript
Positive7-24
The earnings call showed positive financial performance with improved EBITDA and gross margin, strong aerospace and medical sales, and shareholder returns. Despite transportation sales decline, guidance remains optimistic. Analysts' Q&A highlighted growth in therapeutics and potential recovery in transportation. The integration of SyQwest and operational efficiency are progressing well. Overall, the positive financial metrics and optimistic guidance suggest a likely stock price increase in the near term.
CTS Slides
CTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
